Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, retaining the price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the potential of Actinium Pharmaceuticals’ ATNM-400 in addressing unmet needs in oncology. The recent preclinical data presented by Actinium underscore ATNM-400’s promise in treating multiple solid tumors, particularly those that have progressed beyond current standard treatments like Pluvicto for prostate cancer and osimertinib for lung cancer. This potential to extend therapeutic benefits beyond existing options positions ATNM-400 as a significant opportunity in the radiotherapeutic landscape.
Moreover, as the field of radiotherapeutics evolves, there is a growing demand for differentiated approaches. ATNM-400’s emerging profile suggests it could offer a novel alternative outside the common targets in the industry. The strong anti-tumor activity demonstrated in preclinical models, especially in overcoming resistance in non-small cell lung cancer, further supports its potential. These factors collectively contribute to Pantginis’s optimistic outlook for Actinium Pharmaceuticals, justifying the Buy rating.
In another report released on October 14, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.